U.S. License Holder:
Fresenius Kabi
Date of License:
aBLA accepted by FDA May-2024
Last Update:
July-08-2024
FDA-Approved Indications
FKS518 (denosumab) is not FDA-approved. An aBLA has been accepted by the FDA.